摘要
目的观察前列腺癌组织中微管不稳定蛋白(Stathmin)和高迁移率蛋A2(HMGA2)的表达,分析两者与前列腺癌临床病理意义的关系。方法收集2013年1月至2019年8月临沂市人民医院和青岛市立医院治疗并经病理学确诊的23例前腺列增生组织和75例前列腺癌组织标本,前列腺电切术取23例前列腺增生组织标本作为对照组,应用免疫组织化学方法检测其中的Stathmin和HMGA2的表达水平,并结合临床资料进行统计学分析,各组间比较采用χ2检验。结果前列腺癌组织中的Stathmin阳性表达率为80.00%(60/75),明显高于前腺列增生组织阳性表达率21.74%(5/23),差异有统计学意义(t=26.751,P<0.05);Stathmin表达水平与前列腺癌组织学分级、临床分期明显相关(t=7.204、5.357,P<0.05)。前列腺癌组织中HMGA2阳性表达率72.00%(54/75),明显高于前腺列增生组织阳性表达率13.04%(3/23),差异有统计学意义(t=25.143,P<0.05);HMGA2表达水平与前列腺癌组织学分级、精囊腺侵犯和临床分期明显相关(t=9.560、4.734、4.688,P<0.05)。结论Stathmin和HMGA2过度表达在前列腺癌的发生发展过程中发挥一定程度作用。
Objective To investigate the expression of stathmin and high mobility group A2(HMGA2)in prostate carcinoma tissues,and their correlation with the clinicopathological features.Methods Immunohistochemistry was used to assess the expression of Stathmin and HMGA2 in 23 cases of benign prostatic hyperplasia tissues and 75 cases of prostate carcinoma tissues of patients pathologically confirmed From january 2013 to august 2019 on Linyi People’s Hospital and Qingdao Municipal Hospital.χ2 test was used to compare groups.Results The positive rate of Stathmin expression was 80.00%(60/75)in prostate carcinoma tissues,significantly higher than 21.74%(5/23)in benign prostatic hyperplasia tissues(t=26.751,P<0.05).The expression of Stathmin was associated with histological grade and clinical stage(respectively,t=7.204,5.357,P<0.05).The positive rate of HMGA2 expression was 72.00%(54/75)in prostate carcinoma tissues,significantly higher than 13.04%(3/23)in benign prostatic hyperplasia tissues(t=25.143,P<0.05).The expression of HMGA2 was associated with histological grade,seminal vesicle invasion and clinical stage of prostate carcinoma(respectively,t=9.560,4.734,4.688,P<0.05).Conclusion The overexpression of Stathmin and HMGA2 are closely correlated with the onset and progression of prostate carcinoma.
作者
刘敬松
展英华
刘之俊
王世峰
Liu Jingsong;Zhan Yinghua;Liu Zhijun;Wang Shifeng(Department of Urology,Andrology,Linyi People’s Hospital,Linyi 276000,China;Department of Ultrasound,Linyi People’s Hospital,Linyi 276000,China;Department of Urology,Qingdao Municipal Hospital,Qingdao 266071,China;Department of Pathology,Linyi People’s Hospital,Linyi 276000,China)
出处
《中华实验外科杂志》
CAS
CSCD
北大核心
2020年第3期561-563,共3页
Chinese Journal of Experimental Surgery